Cushing's Syndrome: Excess Cortisol

Cushing's syndrome is a disorder caused by prolonged, abnormally elevated cortisol levels in the body, whether that excess originates internally or from external medical treatment. It affects an estimated 10 to 15 people per million annually in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The condition carries significant metabolic, cardiovascular, and psychological consequences if left unaddressed, making accurate classification and timely specialist involvement critical. Readers seeking a broader foundation for how hormonal disorders are evaluated and governed can begin at the endocrinology home page.

Definition and scope

Cushing's syndrome is defined by the National Institutes of Health (NIH) as the clinical state resulting from chronic exposure to excess glucocorticoids — specifically cortisol — regardless of the source. It is distinct from a transient stress-related cortisol spike; the pathology requires sustained hypercortisolism sufficient to produce structural and metabolic changes across organ systems.

The condition is classified into two primary categories based on origin:

Exogenous Cushing's syndrome: Caused by external glucocorticoid administration, most commonly prescribed corticosteroids such as prednisone or dexamethasone. This is the most frequent form encountered in clinical practice, arising from treatment of inflammatory and autoimmune conditions.
Endogenous Cushing's syndrome: Produced by the body's own abnormal cortisol secretion. Endogenous cases are further divided by whether the excess is driven by adrenocorticotropic hormone (ACTH) — termed ACTH-dependent — or by autonomous adrenal cortisol production, termed ACTH-independent.

Within the ACTH-dependent category, Cushing's disease — a specific subset — refers exclusively to cases caused by an ACTH-secreting pituitary adenoma. Cushing's disease accounts for approximately 70% of all endogenous Cushing's syndrome cases (NIDDK), making it the dominant endogenous etiology. The remaining endogenous cases arise from ectopic ACTH-secreting tumors or primary adrenal pathology.

The spectrum of affected systems spans metabolic, musculoskeletal, cardiovascular, dermatologic, and neuropsychiatric domains, which is why adrenal and pituitary symptoms often overlap substantially with Cushing's presentations.

How it works

The hypothalamic-pituitary-adrenal (HPA) axis regulates cortisol through a tightly controlled feedback loop. The hypothalamus releases corticotropin-releasing hormone (CRH), which signals the pituitary to secrete ACTH, which in turn drives the adrenal cortex to produce cortisol. Elevated cortisol normally suppresses CRH and ACTH production — a negative feedback mechanism that maintains physiological balance.

Cushing's syndrome disrupts this loop at one of three levels:

Pituitary level: An ACTH-secreting adenoma secretes ACTH autonomously, partially resistant to normal cortisol feedback suppression, driving bilateral adrenal hyperplasia and sustained cortisol overproduction.
Ectopic level: Tumors outside the pituitary — including small cell lung carcinomas and carcinoid tumors — produce ACTH or CRH independent of hypothalamic regulation, entirely bypassing feedback control.
Adrenal level: Adrenal adenomas, adrenal carcinomas, or bilateral micronodular/macronodular hyperplasia produce cortisol autonomously, suppressing ACTH through negative feedback while cortisol remains pathologically elevated.

Sustained cortisol excess produces characteristic downstream effects: accelerated gluconeogenesis elevating blood glucose, catabolism of muscle and connective tissue causing proximal myopathy and skin fragility, redistribution of fat to central and facial depots, immunosuppression through lymphocyte suppression, and suppression of bone formation contributing to osteoporosis. Hypertension occurs in an estimated 75–80% of patients with endogenous Cushing's syndrome (Endocrine Society Clinical Practice Guideline, 2008, updated 2015).

Common scenarios

Cushing's syndrome presents across a range of clinical contexts, and the presenting pattern often reflects the underlying etiology:

Iatrogenic (exogenous) presentation: The most common scenario involves a patient on long-term systemic corticosteroid therapy for rheumatoid arthritis, asthma, or inflammatory bowel disease developing classic cushingoid features — central obesity, moon face, dorsal fat pad, easy bruising, and glucose intolerance. Inhaled or topical corticosteroids can also cause exogenous Cushing's syndrome, though less frequently.

Pituitary adenoma presentation (Cushing's disease): Typically affects women aged 20–50 more frequently than men, with a female-to-male ratio of approximately 3:1 (NIDDK). Symptoms develop insidiously over months to years. Pituitary tumor disorders are the relevant specialist framework for this subtype.

Ectopic ACTH presentation: Often more abrupt in onset, particularly when associated with aggressive malignancies. Hypokalemia and hyperpigmentation are more prominent due to the extremely high ACTH levels, while classic cushingoid body habitus may be less developed.

Adrenal tumor presentation: More likely to present as ACTH-independent hypercortisolism discovered incidentally on abdominal imaging. Adrenal carcinomas producing cortisol are associated with virilization due to concurrent androgen excess.

Psychiatric symptoms — depression, cognitive impairment, anxiety — occur in 50–80% of Cushing's syndrome patients and may be the most functionally disabling feature (NIH National Institute of Mental Health, referenced in NIDDK documentation).

Decision boundaries

Distinguishing Cushing's syndrome from other conditions and correctly classifying its subtype are both diagnostically demanding. The Endocrine Society recommends a staged diagnostic approach:

Stage 1 — Confirm hypercortisolism (at least two of the following):
1. 24-hour urinary free cortisol (UFC) — elevated on at least two collections
2. Late-night salivary cortisol — elevated on at least two separate measurements
3. Low-dose dexamethasone suppression test (1 mg overnight or 2 mg over 48 hours) — failure to suppress serum cortisol below 1.8 mcg/dL
4. Midnight plasma cortisol — elevated above 7.5 mcg/dL in hospitalized patients

Pseudo-Cushing states — alcoholism, severe depression, obesity, and polycystic ovary syndrome — can generate mildly elevated UFC or impaired dexamethasone suppression, creating a critical decision boundary. A CRH stimulation test following low-dose dexamethasone suppression can help separate true Cushing's syndrome from pseudo-Cushing states.

Stage 2 — Determine ACTH dependency:
- Plasma ACTH below 5 pg/mL indicates ACTH-independent (adrenal) disease; adrenal imaging follows.
- Plasma ACTH above 20 pg/mL indicates ACTH-dependent disease; pituitary MRI and, if nondiagnostic, inferior petrosal sinus sampling (IPSS) are the next steps.

Stage 3 — Locate the source:
IPSS is the definitive test to distinguish pituitary Cushing's disease from ectopic ACTH secretion when MRI is negative or equivocal, with sensitivity exceeding 95% per Endocrine Society guidelines.

The regulatory and professional governance framework for managing these diagnostic protocols — including laboratory reference standards and imaging criteria — is addressed in the regulatory context for endocrinology. Adrenal function testing covers the specific assay protocols used at each diagnostic stage.

Treatment selection depends entirely on etiology: transsphenoidal pituitary surgery for Cushing's disease, adrenalectomy for adrenal adenoma, tumor resection or targeted therapy for ectopic sources, and gradual steroid tapering with HPA axis monitoring for exogenous cases.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)